About Onesource Specialty Pharma Limited
Data last updated: 14 July 2026
Onesource Specialty Pharma Limited is a public limited company based in Thane, Maharashtra, India. It specialises in chemical products, a part of the broader chemicals sector. Incorporated on 12 June 2007, the company has been in operation for over 19 years.
Registered with ROC Mumbai under CIN L74140MH2007PLC432497. Listed.
Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹11.46 Cr. Formerly known as Inbiopro Solutions Private Limited and Stelis Biopharma Private Limited. It is led by directors including Arun Kumar Pillai and Colin Bond Michael.
Last AGM: 22 September 2025. Financial statements filed for year ended 31 March 2025. Office: Sector 30, Thane, Maharashtra.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹1,421.59 Cr, a decline of 1.61% compared to the previous year. The net worth stands at ₹5,831.29 Cr (down 0.84% YoY). Total assets are valued at ₹8,210.01 Cr (up 8.74% YoY).
The company has a workforce of approximately 556 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 2 brands - Stelis Biopharma, Onesource. As per MCA filings, the company has open charges of ₹3,364.09 Cr and satisfied charges of ₹1,444.82 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website stelis.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressUnit No. 902 Cyber One, Plot No – 4 & 6 Sector 30A Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
-
IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited has undergone 2 name changes throughout its history. The company was previously known as Inbiopro Solutions Private Limited, and Stelis Biopharma Private Limited. The current legal name is Onesource Specialty Pharma Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Onesource Specialty Pharma Limited | Current |
| Inbiopro Solutions Private Limited | Previous |
| Stelis Biopharma Private Limited | Previous |
CIN History of Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74140MH2007PLC432497, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L74140MH2007PLC432497 | Current |
| U74140KA2007PLC043095 | Previous |
| U74140KA2007PTC043095 | Previous |
Associated Brands with Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited operates two associated brands: Stelis Biopharma and OneSource. These brands represent Onesource Specialty Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers contract development and manufacturing for drug products globally. | stelis.com | |
| Pharmaceutical contract development and manufacturing services are offered by OneSource. | onesourcecdmo.com |
Competitors & Alternatives of Onesource Specialty Pharma Limited
Brands and companies operating in the same space as Onesource Specialty Pharma Limited include KBI Biopharma, Aldevron, Nephron Pharmaceuticals and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
KBI Biopharma
|
Provider of protein formulation, process & cell line development, and cGMP services | Durham, United States, United States | 1996 |
Aldevron
|
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications | Fargo, United States, United States | 1998 |
Nephron Pharmaceuticals
|
Sterile pharmaceutical products are manufactured and contract services are provided. | Florida, Puerto Rico, United States | 1937 |
Ovagen
|
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services | Mayo, Ireland, Ireland | 2000 |
Suanfarma
|
Generics, nutraceuticals, and APIs are developed by Suanfarma. | Madrid, Spain, Spain | 1993 |
Enzene Biosciences
|
Company specializing in development of Biosimilars | Pune, India, India | 2006 |
Laurus Bio
|
Precision fermentation services for biopharma and food are provided. | Bengaluru, India, India | 2005 |
Quotient Sciences
|
APIs and finished dosage forms are developed and manufactured. | Nottingham, United Kingdom, United Kingdom | 1990 |
Hybio Pharmaceutical
|
Polypeptide drugs and APIs are developed and manufactured. | Shenzhen, China, China | 1998 |
Cytovance
|
Therapeutic proteins and antibodies are manufactured via contract biopharmaceutical services. | Oklahoma City, United States, United States | 2003 |
Business Activity of Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Onesource Specialty Pharma Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited is audited by Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited is currently managed by 8 directors, with 34 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arun Kumar Pillai | Director | 07 Apr 2021 | 5 Years 4 Months | Current |
|
Colin Bond Michael
Also directs:
Onesource Specialty Pharma Limited
|
Director | 23 Jun 2025 | 1 Years 1 Months | Current |
|
Debarati Sen
Also directs:
Onesource Specialty Pharma Limited
|
Director | 27 Feb 2025 | 1 Years 5 Months | Current |
|
Claudio Dr Albrecht
Also directs:
Onesource Specialty Pharma Limited, Dr.Reddy's Laboratories Ltd
|
Director | 27 Feb 2025 | 1 Years 5 Months | Current |
|
Vijay Paul Karwal
Also directs:
Onesource Specialty Pharma Limited
|
Director | 27 Feb 2025 | 1 Years 5 Months | Current |
| Bharat Dhirajlal Shah | Director | 26 Jul 2024 | 2 Years 0 Months | Current |
Financials of Onesource Specialty Pharma Limited FY 2026 filings available
Onesource Specialty Pharma Limited reported revenue of ₹1,421.59 Cr (down 1.61% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹1,421.59 Cr | ₹1,444.85 Cr |
| Other Income | ₹15.02 Cr | ₹17.47 Cr |
| Total Income | ₹1,436.61 Cr | ₹1,462.33 Cr |
| Cost of Materials Consumed | ₹436.76 Cr | ₹328.24 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹30.1 Cr |
| Changes in Inventories | ₹7.89 Cr | ₹76.69 Cr |
| Employee Benefit Expense | ₹242.25 Cr | ₹215.26 Cr |
| Finance Costs | ₹122.19 Cr | ₹166.32 Cr |
| Depreciation & Amortisation | ₹279.09 Cr | ₹273.88 Cr |
| Other Expenses | ₹430.47 Cr | ₹328.05 Cr |
| Total Expenses | ₹1,518.65 Cr | ₹1,418.55 Cr |
| Profit Before Exceptional Items & Tax | -₹82.03 Cr | ₹43.78 Cr |
| Exceptional Items | -₹9.93 Cr | -₹110.85 Cr |
| Profit Before Tax | -₹91.96 Cr | -₹67.07 Cr |
| Total Tax Expense | -₹18.16 Cr | -₹49.79 Cr |
| Net Profit | -₹73.8 Cr | -₹17.97 Cr |
| attributable to Owners | -₹73.8 Cr | - |
| attributable to NCI | ₹0 | - |
| Other Comprehensive Income | ₹16.06 Cr | -₹3.18 Cr |
| Total Comprehensive Income | -₹57.75 Cr | -₹21.15 Cr |
| EBITDA (computed) | ₹319.24 Cr | ₹483.99 Cr |
| Basic EPS | ₹-6.44 | ₹-1.63 |
| Diluted EPS | ₹-6.44 | ₹-1.63 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹8,210.01 Cr | ₹7,550.24 Cr |
| Non-current Assets | ₹6,784.07 Cr | ₹6,464.06 Cr |
| Current Assets | ₹1,425.94 Cr | ₹1,086.18 Cr |
| Property, Plant & Equipment | ₹925.86 Cr | ₹897.35 Cr |
| Inventories | ₹438.96 Cr | ₹158.06 Cr |
| Trade Receivables | ₹690.22 Cr | ₹416.6 Cr |
| Cash & Equivalents | ₹35.68 Cr | ₹156.48 Cr |
| Equity (Net Worth) | ₹5,831.29 Cr | ₹5,880.58 Cr |
| Equity Share Capital | ₹11.46 Cr | ₹11.44 Cr |
| Borrowings (Non-current) | ₹563.7 Cr | ₹219.33 Cr |
| Borrowings (Current) | ₹712.59 Cr | ₹552.26 Cr |
| Total Debt (computed) | ₹1,276.3 Cr | ₹771.59 Cr |
| Current Liabilities | ₹1,441.97 Cr | ₹1,113.56 Cr |
| Total Liabilities | ₹2,378.73 Cr | ₹1,669.66 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹8.52 Cr | -₹21.52 Cr |
| Investing Cash Flow | -₹494.98 Cr | -₹201.08 Cr |
| Financing Cash Flow | ₹359.44 Cr | ₹1,987.17 Cr |
| Capital Expenditure | ₹569.07 Cr | ₹0 |
| Free Cash Flow (computed) | -₹560.55 Cr | -₹21.52 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | -₹127.02 Cr | ₹1,764.58 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹428.22 Cr | ₹290.34 Cr | ₹375.76 Cr | ₹327.27 Cr | ₹425.95 Cr | ₹392.56 Cr | ₹67.98 Cr |
| Other Income | ₹2.09 Cr | ₹4.63 Cr | ₹3.04 Cr | ₹5.27 Cr | ₹2.89 Cr | ₹5.39 Cr | ₹58.2 Lakh |
| Total Income | ₹430.31 Cr | ₹294.97 Cr | ₹378.8 Cr | ₹332.54 Cr | ₹428.84 Cr | ₹397.96 Cr | ₹68.56 Cr |
| Cost of Materials Consumed | ₹144.51 Cr | ₹87.73 Cr | ₹123.55 Cr | ₹83.36 Cr | ₹90.99 Cr | ₹92.86 Cr | ₹12.31 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | -₹7.95 Cr | ₹0 | ₹0 |
| Changes in Inventories | ₹1.76 Cr | ₹6.64 Cr | -₹10.06 Cr | ₹9.56 Cr | ₹27.87 Cr | ₹8.67 Cr | ₹0 |
| Employee Benefit Expense | ₹62.74 Cr | ₹64.19 Cr | ₹62.82 Cr | ₹58.44 Cr | ₹51.06 Cr | ₹57.35 Cr | ₹22.78 Cr |
| Finance Costs | ₹22.51 Cr | ₹38.23 Cr | ₹33.96 Cr | ₹27.48 Cr | ₹33.41 Cr | ₹45.82 Cr | ₹20.73 Cr |
| Depreciation & Amortisation | ₹71.83 Cr | ₹69.64 Cr | ₹69.83 Cr | ₹67.8 Cr | ₹68.49 Cr | ₹68.77 Cr | ₹19.06 Cr |
| Other Expenses | ₹127.29 Cr | ₹114.46 Cr | ₹92.96 Cr | ₹87.43 Cr | ₹81.47 Cr | ₹90.47 Cr | ₹32.77 Cr |
| Total Expenses | ₹430.64 Cr | ₹380.89 Cr | ₹373.06 Cr | ₹334.07 Cr | ₹345.34 Cr | ₹363.94 Cr | ₹107.64 Cr |
| Profit Before Exceptional Items & Tax | -₹32.5 Lakh | -₹85.92 Cr | ₹5.74 Cr | -₹1.53 Cr | ₹83.5 Cr | ₹34.02 Cr | -₹39.08 Cr |
| Exceptional Items | ₹3.3 Lakh | -₹7.09 Cr | ₹0 | -₹2.87 Cr | ₹0 | -₹100.52 Cr | ₹0 |
| Profit Before Tax | -₹29.2 Lakh | -₹93.01 Cr | ₹5.74 Cr | -₹4.4 Cr | ₹83.5 Cr | -₹66.5 Cr | -₹39.08 Cr |
| Total Tax Expense | -₹4.89 Cr | -₹4.31 Cr | -₹4.74 Cr | -₹4.21 Cr | -₹15.39 Cr | ₹2.35 Cr | ₹0 |
| Net Profit | ₹4.6 Cr | -₹88.7 Cr | ₹10.49 Cr | -₹18.6 Lakh | ₹98.2 Cr | -₹68.85 Cr | -₹39.33 Cr |
| attributable to Owners | ₹4.6 Cr | -₹88.7 Cr | - | - | - | ₹0 | ₹0 |
| attributable to NCI | ₹0 | ₹0 | - | - | - | -₹1.87 Cr | ₹0 |
| Other Comprehensive Income | ₹10.66 Cr | -₹3.43 Cr | ₹5.82 Cr | ₹3.01 Cr | ₹2.19 Cr | ₹0 | ₹4.9 Lakh |
| Total Comprehensive Income | ₹15.25 Cr | -₹92.13 Cr | ₹16.3 Cr | ₹2.83 Cr | ₹100.39 Cr | -₹68.85 Cr | -₹39.28 Cr |
| EBITDA (computed) | ₹94.01 Cr | ₹21.95 Cr | ₹109.53 Cr | ₹93.75 Cr | ₹185.41 Cr | ₹148.61 Cr | ₹70.5 Lakh |
| Basic EPS | ₹0.40 | ₹-7.74 | ₹0.92 | ₹-0.02 | ₹8.61 | ₹-6.31 | ₹-9.41 |
| Diluted EPS | ₹0.40 | ₹-7.74 | ₹0.91 | ₹-0.02 | ₹8.59 | ₹-6.31 | ₹-9.41 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹1,405.38 Cr | ₹1,299.59 Cr |
| Other Income | ₹15.01 Cr | ₹17.68 Cr |
| Total Income | ₹1,420.39 Cr | ₹1,317.27 Cr |
| Cost of Materials Consumed | ₹441.26 Cr | ₹330.17 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹2.61 Cr |
| Changes in Inventories | ₹3.27 Cr | ₹75.4 Cr |
| Employee Benefit Expense | ₹240.45 Cr | ₹214.8 Cr |
| Finance Costs | ₹120.58 Cr | ₹161.65 Cr |
| Depreciation & Amortisation | ₹136.8 Cr | ₹134.51 Cr |
| Other Expenses | ₹451.41 Cr | ₹307.33 Cr |
| Total Expenses | ₹1,393.76 Cr | ₹1,226.48 Cr |
| Profit Before Exceptional Items & Tax | ₹26.63 Cr | ₹90.8 Cr |
| Exceptional Items | -₹5.42 Cr | -₹112.25 Cr |
| Profit Before Tax | ₹21.21 Cr | -₹21.46 Cr |
| Total Tax Expense | ₹0 | -₹41.46 Cr |
| Net Profit | ₹21.21 Cr | ₹19.31 Cr |
| Other Comprehensive Income | ₹45.7 Lakh | -₹2.97 Cr |
| Total Comprehensive Income | ₹21.67 Cr | ₹16.35 Cr |
| EBITDA (computed) | ₹284 Cr | ₹386.96 Cr |
| Basic EPS | ₹1.85 | ₹1.81 |
| Diluted EPS | ₹1.85 | ₹1.81 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹8,276.06 Cr | ₹7,390.46 Cr |
| Non-current Assets | ₹6,819.03 Cr | ₹6,366.58 Cr |
| Current Assets | ₹1,457.03 Cr | ₹1,023.88 Cr |
| Property, Plant & Equipment | ₹925.86 Cr | ₹897.35 Cr |
| Inventories | ₹438.96 Cr | ₹153.44 Cr |
| Trade Receivables | ₹735.25 Cr | ₹441.97 Cr |
| Cash & Equivalents | ₹28.06 Cr | ₹83.2 Cr |
| Equity (Net Worth) | ₹5,950.22 Cr | ₹5,920.1 Cr |
| Equity Share Capital | ₹11.46 Cr | ₹11.44 Cr |
| Borrowings (Non-current) | ₹563.7 Cr | ₹219.33 Cr |
| Borrowings (Current) | ₹712.59 Cr | ₹552.26 Cr |
| Total Debt (computed) | ₹1,276.3 Cr | ₹771.59 Cr |
| Current Liabilities | ₹1,523.93 Cr | ₹1,069.48 Cr |
| Total Liabilities | ₹2,325.84 Cr | ₹1,470.36 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹55.18 Cr | -₹46.59 Cr |
| Investing Cash Flow | -₹477.6 Cr | ₹145.78 Cr |
| Financing Cash Flow | ₹361.06 Cr | ₹1,981.97 Cr |
| Capital Expenditure | ₹475.97 Cr | ₹0 |
| Free Cash Flow (computed) | -₹420.8 Cr | -₹46.59 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | -₹61.37 Cr | ₹2,081.15 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹418.96 Cr | ₹290.22 Cr | ₹375.19 Cr | ₹321.01 Cr | ₹477.41 Cr | ₹336.75 Cr | ₹67.98 Cr |
| Other Income | ₹2.09 Cr | ₹4.62 Cr | ₹3.04 Cr | ₹5.26 Cr | ₹3.91 Cr | ₹5.02 Cr | ₹58.4 Lakh |
| Total Income | ₹421.06 Cr | ₹294.84 Cr | ₹378.22 Cr | ₹326.27 Cr | ₹481.32 Cr | ₹341.76 Cr | ₹68.56 Cr |
| Cost of Materials Consumed | ₹145.43 Cr | ₹87.24 Cr | ₹123.43 Cr | ₹87.55 Cr | ₹94.6 Cr | ₹87.35 Cr | ₹12.31 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | -₹8.91 Cr | ₹0 | ₹0 |
| Changes in Inventories | ₹1.76 Cr | ₹6.64 Cr | -₹10.06 Cr | ₹4.94 Cr | ₹26.59 Cr | ₹7.51 Cr | ₹0 |
| Employee Benefit Expense | ₹61.65 Cr | ₹64.06 Cr | ₹62.53 Cr | ₹58.15 Cr | ₹50.94 Cr | ₹57.19 Cr | ₹22.78 Cr |
| Finance Costs | ₹22.25 Cr | ₹37.99 Cr | ₹33.31 Cr | ₹27.03 Cr | ₹32.39 Cr | ₹43.92 Cr | ₹20.71 Cr |
| Depreciation & Amortisation | ₹34.74 Cr | ₹34.57 Cr | ₹34.21 Cr | ₹33.28 Cr | ₹33.59 Cr | ₹33.98 Cr | ₹19.06 Cr |
| Other Expenses | ₹135.42 Cr | ₹119.45 Cr | ₹97.71 Cr | ₹90.5 Cr | ₹77.23 Cr | ₹84.32 Cr | ₹32.77 Cr |
| Total Expenses | ₹401.25 Cr | ₹349.94 Cr | ₹341.12 Cr | ₹301.45 Cr | ₹306.45 Cr | ₹314.26 Cr | ₹107.63 Cr |
| Profit Before Exceptional Items & Tax | ₹19.81 Cr | -₹55.1 Cr | ₹37.1 Cr | ₹24.82 Cr | ₹174.88 Cr | ₹27.5 Cr | -₹39.07 Cr |
| Exceptional Items | ₹1.67 Cr | -₹7.09 Cr | ₹0 | ₹0 | ₹0 | -₹100.52 Cr | -₹95.4 Lakh |
| Profit Before Tax | ₹21.48 Cr | -₹62.19 Cr | ₹37.1 Cr | ₹24.82 Cr | ₹174.88 Cr | -₹73.02 Cr | -₹40.02 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹21.48 Cr | -₹62.19 Cr | ₹37.1 Cr | ₹24.82 Cr | ₹174.19 Cr | -₹73.02 Cr | -₹40.02 Cr |
| Other Comprehensive Income | ₹60,000 | ₹45.1 Lakh | ₹0 | ₹0 | ₹7.9 Lakh | ₹0 | ₹4.9 Lakh |
| Total Comprehensive Income | ₹21.49 Cr | -₹61.73 Cr | ₹37.1 Cr | ₹24.82 Cr | ₹174.27 Cr | -₹73.02 Cr | -₹39.97 Cr |
| EBITDA (computed) | ₹76.8 Cr | ₹17.46 Cr | ₹104.62 Cr | ₹85.13 Cr | ₹240.87 Cr | ₹105.39 Cr | ₹70.7 Lakh |
| Basic EPS | ₹1.87 | ₹-5.43 | ₹3.24 | ₹2.17 | ₹15.28 | ₹-6.69 | ₹-9.63 |
| Diluted EPS | ₹1.87 | ₹-5.43 | ₹3.24 | ₹2.16 | ₹15.25 | ₹-6.69 | ₹-9.63 |
Shareholding Pattern of Onesource Specialty Pharma Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 30.48%, foreign institutional investors hold 17.50%, domestic institutional investors hold 20.61%, retail and other public shareholders hold 31.41% of Onesource Specialty Pharma Limited. The company had 79,460 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 30.48% | 29.93% | 29.77% | 29.79% | 34.25% | 37.77% |
| Public | 69.52% | 70.07% | 70.23% | 70.21% | 65.75% | 62.23% |
| Mar 2026 | Mar 2025 | |
|---|---|---|
| Promoters | 30.48% | 34.25% |
| Public | 69.52% | 65.75% |
| Promoter change (YoY, %pts) | -3.77 | - |
Board & Governance of Onesource Specialty Pharma Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Onesource Specialty Pharma Limited has 8 directors - 5 independent and 1 executive. The board is chaired by Arun Kumar Pillai.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Arun Kumar Pillai | Non-Executive - Non Independent Director · Chairperson | 2021-04-07 | 3 |
| Neeraj Sharma | Executive Director · MD | 2024-03-01 | 1 |
| Debarati Sen | Non-Executive - Independent Director | 2025-02-27 | 1 |
| Claudio Albrecht | Non-Executive - Independent Director | 2025-02-27 | 2 |
| Vijay Paul Karwal | Non-Executive - Independent Director | 2025-02-27 | 1 |
| Bharat Dhirajlal Shah | Non-Executive - Non Independent Director | 2024-07-26 | 1 |
| Rashmi Harshadrai Barbhaiya | Non-Executive - Independent Director | 2024-05-17 | 1 |
| Colin Michael Bond | Non-Executive - Independent Director | 2025-06-23 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Colin Michael Bond (Chairperson), Debarati Sen, Vijay Paul Karwal, Neeraj Sharma |
| Nomination and remuneration committee | Vijay Paul Karwal (Chairperson), Debarati Sen, Claudio Albrecht, Bharat Dhirajlal Shah |
| Stakeholders Relationship Committee | Bharat Dhirajlal Shah (Chairperson), Neeraj Sharma, Rashmi Harshadrai Barbhaiya |
| Risk Management Committee | Vijay Paul Karwal (Chairperson), Neeraj Sharma, Debarati Sen |
| Corporate Social Responsibility Committee | Debarati Sen (Chairperson), Vijay Paul Karwal, Bharat Dhirajlal Shah, Neeraj Sharma |
Group Structure of Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited has 1 subsidiary company. This group structure data is as of FY 2024. The corporate group structure reflects Onesource Specialty Pharma Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Biolexis Private Limited | U24239KA2022PTC156696 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Onesource Specialty Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Jun 2026 | Others | ₹310.58 Cr | Open |
| 28 Jan 2026 | Others | ₹75 Cr | Open |
| 27 Dec 2025 | Yes Bank Limited | ₹100 Cr | Open |
| 15 Dec 2025 | Others | ₹100 Cr | Open |
| 13 Nov 2025 | Others | ₹1,342.49 Cr | Open |
Total charge records: 32 View all charges
Employees and EPFO Compliance at Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited has a workforce of 556 employees as of Mar 10, 2025.
Employee and EPFO history for Onesource Specialty Pharma Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Onesource Specialty Pharma Limited
GST registrations and filing compliance for Onesource Specialty Pharma Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Onesource Specialty Pharma Limited
Credit ratings, litigation, and regulatory alerts for Onesource Specialty Pharma Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Onesource Specialty Pharma Limited
MSME payment history for Onesource Specialty Pharma Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Onesource Specialty Pharma Limited
Corporate group structure for Onesource Specialty Pharma Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Onesource Specialty Pharma Limited
MCA filings and documents for Onesource Specialty Pharma Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Onesource Specialty Pharma Limited
Recent News on Onesource Specialty Pharma Limited
Frequently Asked Questions about Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited is an active public limited company in the chemicals sector based in Thane, Maharashtra, India. It was incorporated on 12 June 2007 (19+ years old) and is registered under CIN L74140MH2007PLC432497. The company has 556 employees.
Onesource Specialty Pharma Limited reported revenue of ₹1,421.59 Cr for FY 2026 (down 1.61% YoY) based on consolidated NSE filings.
The current directors of Onesource Specialty Pharma Limited are:
- Arun Kumar Pillai - Director
- Colin Bond Michael - Director
- Debarati Sen - Director
- Claudio Dr Albrecht - Director
- Vijay Paul Karwal - Director
- Bharat Dhirajlal Shah - Director
- Rashmi Harshadrai Barbhaiya - Director
- Neeraj Sharma - Managing Director
The primary industry of Onesource Specialty Pharma Limited is chemicals. The company specifically operates in chemical products. The company is currently active in this sector.
Yes, Onesource Specialty Pharma Limited is a listed company.
Onesource Specialty Pharma Limited can be reached at the registered office: Unit No. 902 Cyber One, Plot No – 4 & 6 Sector 30A Vashi Navi Mumbai, Thane, Maharashtra, India – 400703, or through the website stelis.com.